Liquid biopsy epigenomic profiling for cancer subtyping
2023 · Nature Medicine · 102 citations
https://doi.org/10.1038/s41591-023-02605-z
B
Brad Fortunato
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
63
Papers
173
Citations
4
h-index
4
i10-index
Brad Fortunato is an academic researcher from Harvard University. The author has contributed to research in topics: Lung Cancer Research Studies & Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment. The author has an h-index of 4, co-authored 54 publications.
ORCID: 0009-0000-6545-4351Papers by this author
worksDecoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription
2024 · Nature Communications · 12 citations
https://doi.org/10.1038/s41467-024-53758-5
Supplementary Table S3 from Detecting Small Cell Transformation in Patients with Advanced <i>EGFR</i> Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
2024 · 0 citations
https://doi.org/10.1158/1078-0432.26926458
Data from Detecting Small Cell Transformation in Patients with Advanced <i>EGFR</i> Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7429470.v1
Supplementary Table S4 from Detecting Small Cell Transformation in Patients with Advanced <i>EGFR</i> Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
2024 · 0 citations
https://doi.org/10.1158/1078-0432.26926452.v1
1714P Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.08.1807
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat